Irinotecan Viatris 300 mg/15 ml inf. sol. (conc.) i.v. vial Bélgica - inglês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

irinotecan viatris 300 mg/15 ml inf. sol. (conc.) i.v. vial

viatris gx bv-srl - irinotecan hydrochloride trihydrate 20 mg/ml - eq. irinotecan 17,33 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan

Irinotecan Viatris 500 mg/25 ml inf. sol. (conc.) i.v. vial Bélgica - inglês - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

irinotecan viatris 500 mg/25 ml inf. sol. (conc.) i.v. vial

viatris gx bv-srl - irinotecan hydrochloride trihydrate 20 mg/ml - eq. irinotecan 17,33 mg/ml - concentrate for solution for infusion - 20 mg/ml - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan

IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 300 mg/15 mL concentrated injection vial Austrália - inglês - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 300 mg/15 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 300 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; hydrochloric acid; sorbitol; water for injections - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN ACCORD irinotecan hydrochloride trihydrate 500 mg/25 mL concentrated injection vial Austrália - inglês - Department of Health (Therapeutic Goods Administration)

irinotecan accord irinotecan hydrochloride trihydrate 500 mg/25 ml concentrated injection vial

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections; lactic acid; sodium hydroxide; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

IRINOTECAN JAZEERA 20 mg/ml concentrate for solution for infusion concentrate for solution for injection Arábia Saudita - inglês - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

irinotecan jazeera 20 mg/ml concentrate for solution for infusion concentrate for solution for injection

jazeera pharmaceutical industries (jpi), saudi arabia - irinotecan - concentrate for solution for injection - 20 mg/ml

IRINOTECAN JAZEERA 20 mg/ml concentrate for solution for infusion concentrate for solution for injection Arábia Saudita - inglês - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

irinotecan jazeera 20 mg/ml concentrate for solution for infusion concentrate for solution for injection

jazeera pharmaceutical industries (jpi), saudi arabia - irinotecan - concentrate for solution for injection - 20 mg/ml

IRINOTECAN HYDROCHLORIDE INJECTION USP SOLUTION Canadá - inglês - Health Canada

irinotecan hydrochloride injection usp solution

pfizer canada ulc - irinotecan hydrochloride - solution - 20mg - irinotecan hydrochloride 20mg - antineoplastic agents

IRINOTECAN HYDROCHLORIDE Irlanda - inglês - HPRA (Health Products Regulatory Authority)

irinotecan hydrochloride

hospira uk limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - irinotecan

Campto concentrate for solution for infusion Armênia - inglês - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

campto concentrate for solution for infusion

pfizer (perth) pty limited - irinotecan (irinotecan hydrochloride trihydrate) - concentrate for solution for infusion - 20mg/ml vial

IRINOTECAN BAXTER irinotecan hydrochloride trihydrate 100 mg/5 mL concentrated injection vial Austrália - inglês - Department of Health (Therapeutic Goods Administration)

irinotecan baxter irinotecan hydrochloride trihydrate 100 mg/5 ml concentrated injection vial

baxter healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium hydroxide; lactic acid; water for injections; hydrochloric acid; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.